Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CASTLE BIOSCIENCES INC
CSTL | US
24.46
USD0.77
3.25%
CSTL | US
Loading StockChartView...
About CASTLE BIOSCIENCES INC
Sector
Healthcare
Industry
Diagnostics & Research
Earnings date
30/06/2024
As of date
24/04/2026
Close
24.46
Open
23.59
High
24.55
Low
23.18
Castle Biosciences Inc. a commercial-stage diagnostics company focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood Texas.
View LessCSTL | US
Risk
46.0
Sharpe
0.17
Luna's Score
60/100
Recommendation
Hold
Luna says (CSTL | US)
What's Working
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
42.8%1 month
46.0%3 months
50.8%6 months
54.3%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.21
Debt to equity
0.06
Debt to assets
0.05
Ent. to EBITDA
75.04
Ent. to rev.
2.44
PEG
-
Other Fundamentals
EBITDA
-2.67M
MarketCap
678.44M
MarketCap(USD)
678.44M
Div. yield
-
Op. margin
5.76
Erngs. growth
-92.60
Rev. growth
73.50
Ret. on equity
-0.77
Short ratio
4.87
Short perc.
6.00
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
3.92
Range1M
4.89
Range3M
22.49
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.11
Price X volume
7.92M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 75.04 | 12.67 | Expensive |
| Ent. to Revenue | 2.44 | 44.00 | Cheaper |
| PE Ratio | - | 40.09 | - |
| Price to Book | 2.21 | 77.50 | Cheaper |
| Dividend Yield | - | 1.18 | - |
| Std. Deviation (3M) | 50.81 | 59.59 | Par |
| Debt to Equity | 0.06 | -14.36 | Expensive |
| Debt to Assets | 0.05 | 0.34 | Cheaper |
| Market Cap | 678.44M | 13.71B | Emerging |
